Completion of PRISMAP: the project radionuclide delivery map
The PRISMAP project – The European medical radionuclides programme, is ending on 31 December 2025. The consortium has just published a press release providing an overview of the user projects funded by the programme.
The main objective of PRISMAP was to facilitate this development phase of radiopharmaceuticals by providing access to novel, high-purity radionuclides for medical research. A network of world-leading European facilities, including nuclear reactors – in particular ILL’s High Flux Reactor – accelerators, and radiochemical laboratories, has been established to offer the broadest catalogue of radioisotopes for medical research.
Over the past five years, PRISMAP has published five calls for user projects from which 47 projects out of the 67 submitted were selected. These projects were proposed by research teams from 19 different countries. 23 different radionuclides, more than three quarters of the portfolio proposed by PRISMAP, were requested, resulting in 159 deliveries for users.
A follow-up project called PRISMAP+ has been submitted for funding in order to continue the work and further strengthen the network over the next three years, in alignment with the European Commission’s commitment to combating the social impact of cancer.
Operating the world’s most intense neutron source for neutron scattering applications, the ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. Today, the dominant application is large-scale production of lutetium-177, the “gold standard” in targeted radionuclide therapy, where this radionuclide is coupled to a biomolecule capable of seeking specifically certain species of cancer cells.
In the very lively field of targeted radionuclide therapies, new molecules are regularly coming into clinical use. Other “emerging” radionuclides produced at ILL are used for fundamental or applied research in medicine, radiobiology, radiochemistry, nuclear physics or atomic physics.
Delivery map where you can track all radionuclide deliveries made during PRISMAP's lifetime. For projects carried out on the user's premises, the transport of radionuclides to the user is indicated, while for projects carried out at PRISMAP's biomedical facilities, the transport of radionuclides and the user's travel to the biomedical facilities are shown.